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Supporting Information 
1. General information 
Rink amide MBHA resins (0.7 mmol/g, 200‒400 mesh) were purchased from Chem-
Impex Int’l Inc. The solid phase syntheses of all compounds were carried out in a peptide 
reaction vessel on a Burrell Wrist-Action shaker. Solvents and other chemicals were ordered 
from either Fisher Scientific or Sigma-Aldrich, and were used without further purification. All 
compounds were analyzed and purified using the Waters Breeze 2 HPLC system under 215 nm 
of UV detector equipped with both analytical and preparative modules. The desired fractions 
were lyophilized on a Labcono lyophilizer.  
 
















Figure S1. γ-AApeptide building blocks. 
Both γ-AApeptide building blocks were used in synthesis of sequences on the solid phase, 
and their procedure of synthesis was reported in previously paper.1  
 
























































Figure S1. Synthesis of compound 10. 
 
Synthetic procedure of the compound 10: 200 mg Rink-amide (MBHA) resin (0.14 mmol) 
was treated with 3 mL 20% piperidine/DMF (v/v) solution for 15 min (× 2) to remove the Fmoc 
protection group, followed by DMF (2 mL × 3) and DCM (2 mL × 3) wash. The attachment of 
Fmoc-L-Phenylalanine to the resin was achieved by adding Fmoc-L-Phenylalanine (155 mg, 
0.4 mmol), DIC (101 mg, 114 μL, 0.8 mmol), and HOBt (122 mg, 0.8 mmol) in 3 mL DMF to 
the reaction vessel, and the reaction was allowed to shake at room temperature for 3 h. The 
solution was drained, and the beads were washed with DCM (3 mL × 3) and DMF (3 mL × 3). 
After that, beads were treated with 3 mL 20% piperidine/DMF (v/v) solution for 15 min (× 2) 
to remove the Fmoc protection group, followed by DMF (2 mL × 3) and DCM (2 mL × 3) wash. 
Then  γ-Lys-BB (238 mg, 0.4 mmol), DIC (101 mg, 114 μL, 0.8 mmol), and HOBt (122 mg, 
0.8 mmol) in 3 mL DMF was added to the reaction vessel, and the reaction was allowed to 
shake at room temperature for 3 h. The solution was drained, and the beads were washed with 
DCM (3 mL × 3) and DMF (3 mL × 3). After that, the resin was treated with Pd(PPh3)4 (24 mg, 
0.02 mmol) and Me2NH.BH3 (70 mg, 1.2 mmol) in 3 mL DCM for 10 min (×2) to remove the 
alloc protein group, then washed with DCM (3 mL x3) and DMF (3 mL ×3). Next, 3-
chlorophenyl isocyanate (77 mg, 61 μL, 0.5 mmol) and DIPEA (65 mg, 87 μL, 0.5 mmol) in 3 
mL DCM were added to the resin and allowed to react for 30 min at room temperature, and 
then the solution was drained. After DMF (2 mL ×3) and DCM (2 mL ×3) wash, beads were 
treated with 3 mL 20% piperidine/DMF (v/v) solution for 15 min (× 2) to remove the Fmoc 
protection group, followed by wash with DMF (2 mL ×3) and DCM (2 mL ×3). Subsequently, 
lauric acid (80 mg, 0.4 mmol), DIC (101 mg, 114 μL, 0.8 mmol), and HOBt (122 mg, 0.8 mmol) 
in 3 mL DMF were added to the reaction vessel and reacted for 3 h. After the solution was 
drained, the beads were washed with DMF (2 mL ×3) and DCM (2 mL ×3), followed by the 
incubation with 4 mL cocktail of 1:1 TFA: DCM 1:1 (v/v) for 2 h to achieve cleavage and 
global deprotection of the compound. After the solvent was removed in vacuo, the residue was 
analyzed and purified on the Waters HPLC system, and the desired fraction was lyophilized to 
give the pure product 10. 
Synthesis of other compounds: The other compounds were synthesized following the 
similar procedure of compound 10. 
Compound 1 
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HRMS (ESI) C38H59ClN6O4 [M+H]+ calc’d = 699.4359; found = 699.5927. 
 
4. Minimum inhibitory concentrations (MICs) assays.2 
All compounds were tested against -three different bacteria strains: Methicillin-resistant S. 
aureus (MRSA, ATCC 33591), Methicillin-resistant S. epidermidis (MRSE, RP62A), 
vancomycin-resistant Enterococcus faecalis (ATCC 700802). One colony of each bacteria was 
incubated in 4 mL TSB buffer overnight at 37 °C, then diluted 100 times and incubated for 
another 6 hours to mid-logarithmic phase. All compounds were diluted in 96-wells plate with 
50 µL 2-fold serial dilution, then 50 µL of diluted bacterial medium (1 × 106 CFU/mL) was 
added to each well. After 20 hours incubation at 37 °C, absorption at 600 nm wavelength was 
read on a Biotek Synergy HT microtiter plate reader. Minimum inhibitory concentrations were 
determined as the lowest concentrations that inhibit bacteria growth completely. 
 
5. Time kill assays.2 
Bacteria MRSA suspensions were incubated at 37 °C to mid-logarithmic phase and diluted to 
1 × 106 CFU/mL, then mixed with compound 10 (12.5, 6.25, 3.125 µg/mL). The mixtures were 
incubated at 37 °C for 10 min, 30 min, 1 h and 2 h respectively, then diluted by 102 to 104 folds 
and 100 µL was spread on TSB agar plates. Numbers of bacteria colonies were counted after 
20 hours incubation at 37 °C.  
 
6. Drug resistance assays. 3 
After MICs assay against MRSA, bacteria from the well which contained 1/2 MIC were diluted 
to 1 × 106 CFU/mL for next MIC measurement. The measurement was repeat for 14 passages. 
 
7. Hemolytic assays.2 
Fresh red blood cells (RBCs) was washed with 1× PBS buffer and centrifuged 10 min at 3500 
rpm less than 3 times until the supernatant was clear, then RBCs in the bottom layer was diluted 
into 5% v/v suspension in 1× PBS. 50 µL of compounds were diluted in 96-wells plate with 2-
fold serial dilution and mixed with 50 µL RBCs suspension, then incubated for 1 hour at 37 °C. 
The mixture was then centrifuged for 10 min at 3500 rpm. 30 µL of the supernatant was added 
to 100 µL PBS, then absorbance of mixture was read on a Biotek Synergy HT plate reader at 
410 nm and 540 nm. The hemolysis activity was calculated by the formula % hemolysis = 
(Abssample-AbsPBS)/(AbsTriton-AbsPBS)x100%. 1% and 5% Triton X-100 were used as positive 
control and 1× PBS buffer was used as negative control. 
 
8. Fluorescence microscopy.2 
Both propidium iodide (PI) and 4’, 6’-diamidino-2-phenylindole dihydrochloride (DAPI) 
fluorescent dyes were used in the study. Bacteria MRSA suspensions were incubated at 37 °C 
to mid-logarithmic phase and diluted 100 folds, then incubated with compound 10 for 2 hours 
at 37 °C. After centrifugation for 15 min at 5000 rpm, cell pellets were washed with 1× PBS 
buffer, and incubated with PI (5 µg/mL) for 15 min on ice in the dark, then washed 2 times with 
PBS. Then DAPI (10 µg/mL) was also applied the same way. The pellets were then diluted in 
100 µL PBS and 10~20 µL was applied on chamber slides and observed under Zeiss Axio Image 
Zloptical microscope using 100× oil-immersion objective. 
 
9. HPLC analysis of compounds 1 ̶ 23. 
Compound Name Retention time(min) Purity (%) 
1 15.77 96.80 
2 23.11 99.59 
3 23.64 99.32 
4 23.67 97.8 
5 28.71 99.58 
6 21.74 99.52 
7 28.05 99.60 
8 27.95 97.35 
9 24.98 99.86 
10 30.51 96.51 
11 34.46 96.40 
12 36.01 97.11 
13 36.47 99.33 
14 24.23 97.51 
15 21.82 95.32 
16 24.14 95.99 
17 24.92 99.17 
18 22.28 99.26 
19 35.98 99.57 
20 21.53 99.60 
21 28.03 99.78 
22 28.12 99.01 
23 37.35 95.20 
Table S1. HPLC purities and retention time of compounds 1 ̶ 23 
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